StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics total assets

Total assets on the balance sheet at the end of each period.

Myriad Genetics's total assets was $638.90M at Jun 30, 2026. For fiscal 2025 it was $706.60M, down 31.2% from the year before. Over ten years it grew -1.5% a year on average. The highest annual figure on record is $1.56B in fiscal 2019.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$706.60M-31.2%
FY2024Dec 31, 2024$1.03B-10.4%
FY2023Dec 31, 2023$1.15B-4.4%
FY2022Dec 31, 2022$1.20B-14.7%
FY2020Jun 30, 2020$1.40B-10.1%
FY2019Jun 30, 2019$1.56B+33.0%
FY2018Jun 30, 2018$1.18B-2.8%
FY2017Jun 30, 2017$1.21B+37.3%
FY2016Jun 30, 2016$880.50M+14.9%
FY2015Jun 30, 2015$766.20M-7.0%
FY2014Jun 30, 2014$823.80M+2.5%
FY2013Jun 30, 2013$803.82M+16.4%
FY2012Jun 30, 2012$690.64M+13.1%
FY2011Jun 30, 2011$610.83M+2.9%
FY2010Jun 30, 2010$593.85M–

Quarterly total assets

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$638.90M-5.7%
Q1 FY2026CQ1 2026Mar 31, 2026$673.70M-33.0%
Q4 FY2025CQ4 2025Dec 31, 2025$706.60M-31.2%
Q3 FY2025CQ3 2025Sep 30, 2025$728.10M-32.7%
Q2 FY2025CQ2 2025Jun 30, 2025$677.30M-37.6%
Q1 FY2025CQ1 2025Mar 31, 2025$1.01B-9.4%
Q4 FY2024CQ4 2024Dec 31, 2024$1.03B-10.4%
Q3 FY2024CQ3 2024Sep 30, 2024$1.08B-5.9%
Q2 FY2024CQ2 2024Jun 30, 2024$1.09B-8.6%
Q1 FY2024CQ1 2024Mar 31, 2024$1.11B-5.0%
Q4 FY2023CQ4 2023Dec 31, 2023$1.15B-4.4%
Q3 FY2023CQ3 2023Sep 30, 2023$1.15B-5.2%
Q2 FY2023CQ2 2023Jun 30, 2023$1.19B-1.9%
Q1 FY2023CQ1 2023Mar 31, 2023$1.17B-6.9%
Q4 FY2022CQ4 2022Dec 31, 2022$1.20B-14.7%
Q3 FY2022CQ3 2022Sep 30, 2022$1.21B-16.2%
Q2 FY2022CQ2 2022Jun 30, 2022$1.21B-23.3%
Q1 FY2022CQ1 2022Mar 31, 2022$1.26B-21.1%
Q4 FY2020CQ2 2020Jun 30, 2020$1.40B-10.1%
Q3 FY2020CQ1 2020Mar 31, 2020$1.45B-7.1%
Q2 FY2020CQ4 2019Dec 31, 2019$1.58B+1.4%
Q1 FY2020CQ3 2019Sep 30, 2019$1.59B+1.1%
Q4 FY2019CQ2 2019Jun 30, 2019$1.56B+33.0%
Q3 FY2019CQ1 2019Mar 31, 2019$1.56B+27.8%
Q2 FY2019CQ4 2018Dec 31, 2018$1.56B+26.7%
Q1 FY2019CQ3 2018Sep 30, 2018$1.57B+28.1%
Q4 FY2018CQ2 2018Jun 30, 2018$1.18B-2.8%
Q3 FY2018CQ1 2018Mar 31, 2018$1.22B-3.9%
Q2 FY2018CQ4 2017Dec 31, 2017$1.23B-3.7%
Q1 FY2018CQ3 2017Sep 30, 2017$1.23B-3.4%
Q4 FY2017CQ2 2017Jun 30, 2017$1.21B+37.3%
Q3 FY2017CQ1 2017Mar 31, 2017$1.27B+46.0%
Q2 FY2017CQ4 2016Dec 31, 2016$1.28B+46.4%
Q1 FY2017CQ3 2016Sep 30, 2016$1.27B+61.5%
Q4 FY2016CQ2 2016Jun 30, 2016$880.50M+14.9%
Q3 FY2016CQ1 2016Mar 31, 2016$868.20M+11.4%
Q2 FY2016CQ4 2015Dec 31, 2015$871.70M–
Q1 FY2016CQ3 2015Sep 30, 2015$787.00M–
Q4 FY2015CQ2 2015Jun 30, 2015$766.20M–
Q3 FY2015CQ1 2015Mar 31, 2015$779.05M–

More Myriad Genetics figures

See a number that looks wrong?